1. The Leukemia & Lymphoma Society Launches IMPACT Research Grants to Help Underserved Patients Access Clinical Trials

    Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials RYE BROOK, N.Y., May 6, 2021 – The Leukemia & Lymphoma Society (LLS) announced today the launch of the IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants to increase enrollment of individuals from underrepresented communities in clinical tri...

    Read More
  1. Highlights from AACR 2021

    The first big oncology meeting of the year, American Association for Cancer Research (AACR) kicked off with week one of the meeting held from April 10-15, 2021. Key topics from the virtual meeting include concerns for blood cancer patients such as building COVID-19 vaccine confidence and addressing cancer health disparities, as well as research into ways to improve CAR T-cell immunotherapy. Read on for a closer look at the top news from AACR: Building Vaccine Confidence I was invited...

    Read More
  2. May 2021 Patient Education Programs

    Living Well with Leukemia, Lymphoma, and Myeloma: An Integrative Workshop for Patients and Caregivers A Virtual Education Program (Desert) May 1, 2021 10:00am – 12:00pm (PT) https://www.lls.org/events/living-well-with-leukemia-lymphoma-and-myeloma-az Young Adult Cancer Survivorship A Virtual Education Program (New England) May 4, 2021 6:00pm – 8:00pm (ET) https://www.lls.org/events/YA-Cancer-Survivorship Blood Cancer Related Fatigue: Developing Your Own Personalized Care Pla...

    Read More
  3. Statement on Recent mRNA-based COVID-19 Vaccines Studies for Blood Cancer Patients

    The Leukemia & Lymphoma Society (LLS) has heard from blood cancer patients and caregivers who are concerned about new research suggesting that mRNA-based COVID-19 vaccines may offer less protection for people with certain blood cancers. The findings from the new research confirm what LLS and other experts expected: that certain types of blood cancer and blood cancer treatments could affect vaccine response. Additional research is underway including collection of real-world data in the ...

    Read More
  1. COVID-19 VACCINE SAFETY AMONG BLOOD CANCER PATIENTS

    Background and Purpose Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown. The Leukemia & Lymphoma Society National Patient Registry, created in honor of Michael...

    Read More
  2. Research Highlight: Breakthroughs in Acute Myeloid Leukemia

    April 21st was AML Awareness Day! Recent breakthroughs have led to unprecedented new treatment approvals for AML. In this highlight, we focus on some targeted therapy approaches. Acute myeloid leukemia (AML) is an aggressive, rapidly-progressing disease in which the immature blood cells do not develop properly and grow uncontrollably. The AML cells crowd out and interfere with the number and function of normal blood cells. The need for new treatments for AML remains urgent, which is w...

    Read More
  3. FDA Approval of New Treatment Option for Children with Secondary Acute Myeloid Leukemia is a Welcome Step Forward

    Here at The Leukemia & Lymphoma Society (LLS), we applaud every advance for children with blood cancers. Today's reason to celebrate is the news that the U.S. Food and Drug Administration (FDA) expanded the approval of daunorubicin and cytarabine (Vyxeos®) to include treatment of pediatric patients aged one year and older with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). This is a welcome and necessary advancement in...

    Read More
  4. Celebrating Survivorship: Haider Albaldawy

    I was diagnosed with non-Hodgkin lymphoma in mid-2015. It was the most difficult day of my life because I was alone in the USA at this time; I had no friends. I did not speak English even though I was a civil engineer in my country. The hardest of all, my family did not come with me. I have four daughters who I love madly and they love me so much. I felt that I would never seen them again; it was a feeling so hard to describe. My love for them made me decide to be stronger and fight the d...

    Read More
  5. LLS and 30 patient organizations take action to protect patients from substandard insurance

    Health insurance is supposed to protect patients when they need help the most. When it works for patients the way it’s supposed to, it keeps their costs affordable and ensures they can get the life-saving treatment they need. But what do you call health “insurance” that’s not there when you need it most? We call it “substandard” coverage, and LLS just took another major action to sound the alarm on this problem. Thirty patient organizations, led by LLS, just published the ...

    Read More
  6. April 2021 - Patient Education Programs

    Diffuse Large B-Cell Non-Hodgkin Lymphoma: Diagnosis, Treatment, and Nutrition A Virtual Education Program (Lower Plains Region) April 6, 2021 6:00pm – 7:30pm (CT) https://www.lls.org/events/dlbcl Adolescent and Young Adult Survivorship: Special Considerations A Virtual Education Program (NJ-Metro NY-CT-HV Regions) April 7, 2021 4:00pm – 6:00pm (ET) https://www.lls.org/events/Adolescent-and-Young-Adult-Survivorship Young Adult Cancer Survivorship A Virtual Education Program...

    Read More